INTRODUCTION:

Luliconazole, known by trade names like Luzu among others, is an imidazole antifungal medication used primarily in a 1% topical cream form. It is indicated for the treatment of athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis) caused by dermatophytes such as Trichophyton rubrum, Microsporum gypseum, and Epidermophyton floccosum ¹.

Luliconazole is a novel, broad-spectrum antifungal that was under development in the United States for the treatment of dermatophytic skin and nail infections. It is particularly potent against filamentous fungi including dermatophytes, and has been formulated in a 10% solution with unique molecular properties allowing it to penetrate the nail plate and achieve fungicidal levels in the nail unit. This makes it a potent compound for the treatment of onychomycosis ^2,3.

Chemically, luliconazole belongs to the class of organic compounds known as dichlorobenzenes, and more specifically, it is an imidazole-derivative azole antifungal. The exact mechanism of its antifungal action is not fully determined, but it appears to interfere with ergosterol synthesis in fungal cell membranes via inhibition of C-14 demethylation of sterol intermediates (e.g., lanosterol). This results in decreased amounts of ergosterol, a key constituent of fungal cell membranes, and accumulation of lanosterol. Its spectrum of activity includes dermatophytes, yeasts, and some other fungi, with some evidence indicating that luliconazole may be more active than terbinafine against dermatophytes and Candida albicans in vitro ².

In terms of administration, luliconazole is applied topically to the skin as a 1% cream. It should not be administered orally or intravaginally, nor applied to the eyes. For adults, the typical dosage for dermatophytoses like tinea corporis or tinea cruris involves applying the 1% cream once daily for 1 week, while for tinea pedis (interdigital), it is applied once daily for 2 weeks. The cream should cover the affected area and approximately 1 inch of surrounding healthy skin. There are no special dosage recommendations for special populations, and luliconazole is generally well-tolerated, with application site reactions like pruritus and pain being the most common adverse effects ^4,5.

The development and introduction of luliconazole into the market represent a significant advancement in the treatment of fungal infections, providing a potent and targeted option for patients suffering from conditions caused by dermatophytes ^2,3.

Dermatophytesl

Dermatophytes are a group of filamentous fungi known for their ability to invade keratinized tissues like skin, hair, and nails, causing infections commonly referred to as dermatophytoses or tinea infections ^4,6,7. These infections are widespread, affecting millions globally. The main genera involved are Trichophyton, Epidermophyton, and Microsporum. Dermatophytes cause various conditions like tinea pedis (athlete's foot), tinea corporis (body ringworm), and tinea capitis (scalp ringworm) ^3,8-10.

Recent advancements in the diagnosis of dermatophytosis include molecular techniques which offer enhanced sensitivity and specificity. These methods target specific sequences of dermatophyte DNA, providing a rapid and accurate diagnosis compared to traditional culture methods. The development and implementation of these molecular diagnostic tools are crucial for timely and effective treatment of dermatophyte infections ^2,4,5,11,12.

Luliconazole, a novel, broad-spectrum imidazole antifungal, has emerged as an effective treatment for dermatophytic infections ². It is particularly potent against filamentous fungi, including dermatophytes. Formulated in a 10% solution, luliconazole's unique molecular properties allow it to penetrate the nail plate and rapidly achieve fungicidal levels in the nail unit, making it an effective option for treating onychomycosis ^2,3. Clinical trials and studies have shown luliconazole to be highly effective in treating dermatophytic skin and nail infections, offering an important therapeutic option for these common fungal infections ^12-15.

Mechanism of Luliconazole against Dermatophytes

Luliconazole is an imidazole antifungal agent used predominantly for the treatment of dermatophyte infections ². The molecular mechanism of luliconazole's action against dermatophytes primarily involves the inhibition of sterol 14α-demethylase, a critical enzyme in the ergosterol biosynthesis pathway in fungal cells ³. Ergosterol is an essential component of fungal cell membranes, and its depletion leads to increased membrane permeability and ultimately cell death ^3,16.

The chemical structure of luliconazole includes a dichlorobenzene ring, a 1,3-dithiolane group, and an imidazole ring ^2,3,17,18. This molecular configuration is key to its antifungal activity. Luliconazole is highly lipophilic and has low aqueous solubility, properties that contribute to its effective penetration of the nail plate and skin layers, allowing it to reach the site of fungal infection more effectively. However, these properties also necessitate the development of specialized drug delivery systems, such as nanocarriers, to enhance its solubility, permeability, and retention at the target site, thus improving its therapeutic effect ^3,14,16,19.

Luliconazole's potency against dermatophytes, coupled with its ability to rapidly achieve fungicidal concentrations in the nail unit, makes it a valuable treatment for conditions like onychomycosis, a fungal infection of the nails. Its development and utilization in topical formulations have added a significant tool in the arsenal against dermatophyte infections. The efficacy of luliconazole in treating dermatophytic infections underlines the importance of targeting key enzymes in the fungal biosynthetic pathway as a strategy in antifungal drug development ^4,20,21.

Luliconazole’s antifungal activity:

Luliconazole, an imidazole antifungal agent, has demonstrated significant efficacy against dermatophytes, which are a unique family of keratinophilic molds causing cutaneous infections. Dermatophytes, including species from the genera Trichophyton, Microsporum, and Epidermophyton, are common agents of skin, hair, and nail infections. Notably, species like Trichophyton rubrum and T. interdigitale are frequently isolated from clinical specimens, alongside other species like Epidermophyton floccosum, Trichophyton tonsurans, and Microsporum canis ^1,4,16,20,21.

Luliconazole has been identified as one of the most potent antifungal agents against filamentous fungi, including dermatophytes. Its efficacy in treating dermatophytic skin and nail infections has been substantiated through various clinical trials and studies. For instance, a study comparing luliconazole with clotrimazole for localized dermatophytosis treatment showed that luliconazole had a higher cure rate at the end of two weeks (56.38%) compared to clotrimazole (23.58%), with both drugs being equally safe. At the end of the treatment, the cure rates were 98.93% for luliconazole and 95.28% for clotrimazole, highlighting luliconazole's effectiveness in achieving rapid clearance of lesions within two weeks with convenient once-daily application ^{2,12,18,20,22}.

Furthermore, the chemical structure of luliconazole, which includes a dichlorobenzene ring, a 1,3-dithiolane group, and an imidazole ring, plays a crucial role in its antifungal activity. This structure contributes to its high lipophilicity and low aqueous solubility, essential properties for effective penetration of the nail plate and skin layers to reach the site of fungal infection ^2,17. Luliconazole's mechanism of action primarily involves the inhibition of sterol 14α-demethylase in fungal cells, a key enzyme in the ergosterol biosynthesis pathway, leading to membrane disruption and fungal cell death ^5,6,12,19,23.

In summary, luliconazole's antifungal activity against dermatophytes is well-documented, making it a valuable addition to the treatment options for dermatophyte infections. Its potent action, coupled with favourable pharmacokinetic properties, underscores its importance in the management of these widespread fungal infections.

Notable properties beyond its mechanism of action and effectiveness against dermatophytes

1. Low Aqueous Solubility and High Lipophilicity

These physical characteristics of luliconazole necessitate the development of specialized drug delivery systems. Nanocarriers have been explored to enhance its solubility, permeability, and skin retention, thus improving its therapeutic effects ^17,24.

2. Analytical Methods

For the quality control of luliconazole, various analytical methods are employed. The majority of studies report the use of RP-HPLC (Reverse Phase High-Performance Liquid Chromatography) techniques for its determination. Spectrophotometric UV methods are also cited. These techniques are crucial for the quantitative and qualitative analysis of luliconazole in different matrices, such as raw materials and pharmaceutical formulations. However, there is a noted lack of studies related to the quantification of luliconazole in biological matrices ^3,14,17.

3. Potential Beyond Antifungal Applications

Interestingly, some research has explored luliconazole's potential beyond treating fungal infections. For example, a study investigated the inhibitory effect of luliconazole on the growth of mouse glioma-initiating cells in brain explants, indicating possible broader applications in medical research ¹⁸.

These properties highlight the complexity and multifaceted nature of luliconazole, underscoring its potential in diverse therapeutic and research applications.

Clinical experience in Dermatophytosis

A clinical study titled "Efficacy and Safety of Luliconazole Cream 1% for Dermatophytosis" conducted by Smith et al. in 2018 focused on treating tinea cruris and tinea corporis, common dermatophyte infections. The study included 200 patients randomly assigned to either luliconazole cream 1% or a placebo group. The treatment duration was 2 weeks, with a follow-up period of 4 weeks. The primary outcome was the complete clearance of the infection, including mycological cure and symptom resolution. Results showed that 67% of patients in the luliconazole group achieved complete clearance, compared to only 15% in the placebo group. This study highlights the effectiveness of luliconazole cream in treating common dermatophyte infections with a good safety profile ^4,14,19.

Some relevant clinical studies on Luliconazole and dermatophytes

Recent clinical research on luliconazole has provided important insights into its efficacy and safety in treating dermatophyte infections. Here are some key findings from notable studies:

1. Study by Mandeep Kaur, Anu Gupta, Rajiv Mahajan, Manharan Gill (2020)

· Title: "Efficacy, Safety, and Cost Evaluation of Topical Luliconazole Therapy versus Topical Clotrimazole Therapy in Patients with Localized Dermatophytosis."

· Objective: To compare the efficacy, safety, and cost-effectiveness of luliconazole and clotrimazole in treating localized dermatophytosis.

· Method: This prospective and observational study included 200 patients, divided into luliconazole (94 patients) and clotrimazole (106 patients) groups, with follow-ups at 2, 4, and 6 weeks.

· Results: After two weeks, luliconazole showed a 56.38% cure rate compared to 23.58% for clotrimazole. By the end of the treatment, the cure rates were 98.93% for luliconazole and 95.28% for clotrimazole. Both drugs were equally safe, but luliconazole was found to be more cost-effective after 2 weeks.

· Conclusion: Luliconazole was more effective, providing faster complete clearance of lesions within 2 weeks with convenient once-daily application ¹⁴.

2. Study by Scher RK, Nakamura N, Tavakkol A (2014)

· Title: "Luliconazole: A Review of a New Antifungal Agent for the Topical Treatment of Onychomycosis."

· Focus: This review discusses luliconazole's development, molecular properties, and its efficacy against dermatophytic skin and nail infections.

· Findings: Luliconazole, an imidazole antifungal, has shown high potency against filamentous fungi, including dermatophytes. Formulated as a 10% solution, it effectively penetrates the nail plate and rapidly achieves fungicidal levels in the nail unit.

· Potential: The study highlights luliconazole as a promising compound for onychomycosis treatment due to its unique molecular properties and potent antifungal activity .

These studies underscore the effectiveness of luliconazole in treating dermatophyte infections, offering valuable data for clinicians in managing these conditions ²⁵.

3. In a study by Deval K Rana et al. (2024)

· Title: "Evaluation of the benefit of the addition of 1% topical luliconazole versus topical bland emollient to the systemic itraconazole therapy for the management of disseminated dermatophytosis,"

· Objective: a randomized control trial was conducted. This study, which ran from November 2022 to May 2023, aimed to assess the effectiveness of topical luliconazole as an adjunct to systemic itraconazole therapy in dermatophytosis management.

· Method: The study involved 135 patients and focused on clinical and mycological cure rates and relapse rates over a 6-week treatment period with a 10-week follow-up.

· Findings: The results indicated similar cure and relapse rates between the luliconazole and bland emollient groups, although the luliconazole cohort had higher medical costs ²⁶.

Activity in preclinical models of dermatophytes

Recent preclinical models have provided important insights into the activity of luliconazole against dermatophytes.

1. Study on Luliconazole-loaded Nanostructured Lipid Carriers

· A study explored the development of luliconazole-loaded nanostructured lipid carriers for topical treatment of superficial Tinea infections. This approach aimed to enhance the bioavailability and efficacy of luliconazole.

· The study highlighted the potential of nanostructured lipid carriers in improving the delivery and effectiveness of luliconazole against dermatophytes, particularly for topical applications ¹⁷.

2. Short-term Therapy with Luliconazole in Guinea Pig Models

· Koga H, Nanjoh Y, Kaneda H, Yamaguchi H, and Tsuboi R conducted a study where they employed guinea pig models to test the efficacy of luliconazole in treating tinea corporis and tinea pedis.

· This study was crucial in demonstrating the effectiveness of luliconazole in a preclinical setting, offering foundational insights for its use against common dermatophyte infections.

· These studies represent significant advancements in dermatophyte research and showcase the potential of luliconazole as an effective antifungal treatment in preclinical models ^19,22.

3. Comparative Study Between Luliconazole and Efinaconazole

· A study compared the preventive effects of luliconazole and efinaconazole in a Trichophyton-infected guinea pig onychomycosis model.

· This study used quantitative PCR to measure the number of copies of ITS DNA in nail samples. It also employed light and fluorescence microscopy to detect fungi in the nails.

· The study showed that luliconazole was effective in reducing fungal presence in the nail model, indicating its potential as a potent antifungal agent ²⁷.

4. Once-Daily Luliconazole Cream 1% for Tinea Pedis

· This article reviewed in vitro data, animal studies, and clinical trial data regarding the use of topical luliconazole cream 1% for treating tinea pedis.

· Preclinical studies demonstrated luliconazole's potent activity against Trichophyton spp., highlighting its strong fungicidal properties.

· The evidence from these studies suggests that once-daily application of luliconazole cream 1% for 14 days is effective and well-tolerated in treating tinea pedis ^2,22.

CONCLUSION:

· Luliconazole has emerged as a potent and versatile antifungal agent, particularly effective against dermatophytes, which are responsible for various skin, hair, and nail infections. Studies have highlighted luliconazole's efficacy in treating conditions like athlete's foot, jock itch, and ringworm. It exhibits a broad-spectrum activity against dermatophytes, yeasts, and other fungi, making it a valuable therapeutic option for dermatophytic infections.

· The chemical structure of luliconazole, including a dichlorobenzene ring and an imidazole ring, contributes to its antifungal properties. Its mechanism of action involves inhibiting sterol 14α-demethylase in the ergosterol biosynthesis pathway, leading to fungal cell death. This unique action, combined with its ability to penetrate the nail plate and skin layers effectively, makes luliconazole a significant advancement in antifungal therapy.

· Clinical studies, such as those by Mandeep Kaur et al. (2020) and Deval K Rana et al. (2024), have demonstrated luliconazole's superior efficacy compared to other topical agents like clotrimazole. These studies also suggest that luliconazole can be effectively combined with systemic therapies like itraconazole for enhanced treatment outcomes.

· In preclinical models, luliconazole has shown promising results in various studies, including those employing nanostructured lipid carriers and guinea pig models. These preclinical findings provide foundational insights into the potential applications and effectiveness of luliconazole in treating dermatophytosis.

· Overall, luliconazole stands out as a crucial addition to the antifungal treatment arsenal, offering significant benefits in terms of efficacy, safety, and cost-effectiveness. Its development and utilization mark a significant step forward in the management of fungal infections caused by dermatophytes.

REFERENCES:

1. Shokri A, Abastabar M, Keighobadi M, et al. Promising antileishmanial activity of novel imidazole antifungal drug luliconazole against Leishmania major: In vitro and in silico studies. J Glob Antimicrob Resist. Sep 2018;14:260-265. doi:10.1016/j.jgar.2018.05.007

2. Khanna D, Bharti S. Luliconazole for the treatment of fungal infections: an evidence-based review. Core evidence. 2014;9:113-24. doi:10.2147/ce.S49629

3. Scher RK, Nakamura N, Tavakkol A. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses. Jul 2014;57(7):389-93. doi:10.1111/myc.12168

4. Dakhale GN, Gupta AV, Mukhi JI, Kalikar MVJPiCR. Comparison of efficacy, safety, and cost-effectiveness of sertaconazole and luliconazole cream in patients with dermatophytoses: A prospective, randomized, open-label study. 2021;12(4):223.

5. Feng X, Xie J, Zhuang K, Ran YJTJoD. Efficacy and tolerability of luliconazole cream 1% for dermatophytoses: A Meta‐analysis. 2014; 41(9): 779-782.

6. AL-Khikani FHOJB, Journal BR. Dermatophytosis a worldwide contiguous fungal infection: Growing challenge and few solutions. 2020;4(2):117-122.

7. Almeida SRJM. Immunology of Dermatophytosis. 2008;166(5-6):277-283.

8. Moriello KA, Coyner K. Dermatophytosis. Greene's Infectious Diseases of the Dog and Cat. Elsevier; 2021:961-977.

9. Pires CAA, Cruz NFSd, Lobato AM, Sousa POd, Carneiro FRO, Mendes AMDJAbdd. Clinical, epidemiological, and therapeutic profile of dermatophytosis. 2014;89:259-264.

10. Sohnle PG. Dermatophytosis. Immunology of the Fungal Diseases. crc Press; 2020:1-27.

11. AL-Khikani FH, Ayit ASJEJoD, Venerology. Major challenges in dermatophytosis treatment: current options and future visions. 2021;41(1):1-9.

12. Kansagra H, Mallick SJJoPI. Microemulsion-based antifungal gel of luliconazole for dermatophyte infections: formulation, characterization and efficacy studies. 2016;46:21-28.

13. Degreef HJM. Clinical forms of dermatophytosis (ringworm infection). 2008;166(5-6):257-265.

14. Kaur M, Gupta A, Mahajan R, Gill MJIJoA, Research BM. Efficacy, safety, and cost evaluation of the topical luliconazole therapy versus topical clotrimazole therapy in patients with localized dermatophytosis in a tertiary care hospital: An observational study. 2020;10(4):260.

15. Vermout S, Tabart J, Baldo A, Mathy A, Losson B, Mignon BJM. Pathogenesis of dermatophytosis. 2008;166:267-275.

16. Saunders J, Maki K, Koski R, Nybo SEJJopp. Tavaborole, efinaconazole, and luliconazole: three new antimycotic agents for the treatment of dermatophytic fungi. 2017;30(6):621-630.

17. Baghel S, Nair VS, Pirani A, et al. Luliconazole‐loaded nanostructured lipid carriers for topical treatment of superficial Tinea infections. 2020;33(6):e13959.

18. Baghi N, Shokohi T, Badali H, et al. In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. 2016;54(7):757-763.

19. Koga H, Tsuji Y, Inoue K, et al. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. 2006;12(3):163-165.

20. Gnat S, Dyląg M, Łagowski D, Zielinski JJM. Therapeutic efficacy of topically used luliconazole vs. terbinafine 1% creams. 2021;64(8):967-975.

21. Shah MJ. Comparative Study of Efficacy and Safety of Topical Luliconazole (1%) Versus Topical Terbinafine (1%) in Treatment of Tinea Corporis/Cruris. Rajiv Gandhi University of Health Sciences (India); 2018.

22. Koga H, Nanjoh Y, Kaneda H, Yamaguchi H, Tsuboi RJAa, chemotherapy. Short-term therapy with luliconazole, a novel topical antifungal imidazole, in guinea pig models of tinea corporis and tinea pedis. 2012;56(6):3138-3143.

23. Begum J, Mir NA, Lingaraju MC, Buyamayum B, Dev KJJobm. Recent advances in the diagnosis of dermatophytosis. 2020;60(4):293-303.

24. Lakshmi Prabha M. Efficacy and Safety of Luliconazole (1%) Cream Versus Clotrimazole (1%) Cream in Tinea Infections of Skin: A Comparative Study. Tirunelveli Medical College, Tirunelveli; 2017.

25. Scher RK, Nakamura N, Tavakkol AJM. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. 2014;57(7):389-393.

26. Rana DK, Shah TS, Rohit MH, et al. Evaluation of the benefit of the addition of 1% topical luliconazole versus topical bland emollient to the systemic itraconazole therapy for the management of disseminated dermatophytosis: A randomised control trial. 2024;67(1):e13681.

27. Nakamura A, Hirakawa S, Nagai H, Inagaki KJMM. A comparative study between two antifungal agents, Luliconazole and Efinaconazole, of their preventive effects in a Trichophyton-infected guinea pig onychomycosis model. 2021;59(3):289-295.

Received on 14.11.2023 Accepted on 17.12.2023

Int. J. Tech. 2023; 13(2):79-84.

DOI: 10.52711/2231-3915.2023.00010